Marazziti D, Placidi G F, Cassano G B, Akiskal H S
School in Applied Biochemistry, University of Pisa, Italy.
Psychiatry Res. 1989 Oct;30(1):21-9. doi: 10.1016/0165-1781(89)90168-6.
We compared 3H-imipramine binding in 10 major depressives with that in 29 healthy volunteers, 13 patients with panic disorder, 9 patients with bulimia, 9 suicide attempters, and 6 schizophrenic patients. None of the comparison groups had histories of major mood disorders, except the suicide attempters. We found a significant reduction of the maximum binding capacity (Bmax) in all groups of patients as compared with healthy controls. These data cast doubt upon the specificity of the decrease of platelet 3H-imipramine binding in major depression, but suggest a possible pharmacological common denominator involving the serotonin system.
我们比较了10名重度抑郁症患者、29名健康志愿者、13名惊恐障碍患者、9名贪食症患者、9名自杀未遂者和6名精神分裂症患者的3H-丙咪嗪结合情况。除自杀未遂者外，其他比较组均无重度情绪障碍病史。我们发现，与健康对照组相比，所有患者组的最大结合容量（Bmax）均显著降低。这些数据对重度抑郁症中血小板3H-丙咪嗪结合减少的特异性提出了质疑，但提示可能存在涉及血清素系统的药理学共同特征。
